Orthospace Ltd develops and commercializes simple-to-implant, biodegradable balloon systems for the Orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures. The company’s first product- the InSpace™ System is indicated for Rotator Cuff syndrome as it alleviates pain in patients. The InSpace™ System has the CE mark and is commercially available in Europe. In the USA, the InSpace is an investigational device. Limited by Federal (or United States) law to investigational use. Exclusively for clinical investigations.
Looking for a particular OrthoSpace - Acquired by Stryker (NYSE:SYE) employee's phone or email?
OrthoSpace - Acquired by Stryker (NYSE:SYE) Questions
The OrthoSpace - Acquired by Stryker (NYSE:SYE) annual revenue was $4 million in 2026.
Yossi Ben-Zaken is the CFO of OrthoSpace - Acquired by Stryker (NYSE:SYE).
8 people are employed at OrthoSpace - Acquired by Stryker (NYSE:SYE).
OrthoSpace - Acquired by Stryker (NYSE:SYE) is based in Caesarea, Haifa.
The NAICS codes for OrthoSpace - Acquired by Stryker (NYSE:SYE) are [339, 33].
The SIC codes for OrthoSpace - Acquired by Stryker (NYSE:SYE) are [384, 38].
Top OrthoSpace - Acquired by Stryker (NYSE:SYE) Employees
Related Companies
